Sign in
Taking people in United StatesNo phase

Tests whether lab-grown tumor tissue predicts osteosarcoma chemotherapy response

Studies whether lab-grown tumor cultures from biopsies can predict osteosarcoma response to chemotherapy.

Key facts

Who runs it
Jonsson Comprehensive Cancer Center
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
Status
Recruiting
People taking part
40 people, planned
Started
12 Feb 2024
Expected to end
1 Jan 2028
Type of study
Observational, 2 groups
Treatments tested
  • standard of care biopsy
Record updated
11 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people whose scans suggest osteosarcoma (a bone cancer) and who are already planned to have a biopsy or surgery to confirm the diagnosis.

Sex
All sexes can join.
Disease stage
Group 1: scans suggest osteosarcoma, not yet diagnosed. Group 2: scans suggest osteosarcoma that has spread (metastatic).

The registry criteria, word for word

Show all 3 criteriaShow less

Other criteria

  • Inclusion / exclusion criteria - Group1:
  • Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes; Inclusion / exclusion criteria - Group 2:
  • Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Where in United States

  • UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, United StatesContact: Summer SwearingenTaking people

About the trial

What the trial wants to find out

The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.

The 2 groups in the trial

  • Group 1: local tumor

    patients with localized osteosarcoma who are scheduled to undergo diagnostic biopsy and are planned for surgical excision of the primary tumor

    Treatment: standard of care biopsy

  • Group 2: metastatic disease

    patients with metastatic osteosarcoma who are scheduled to undergo either biopsy or surgery of metastatic disease

    Treatment: standard of care biopsy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST
Plain-language title
Tests whether lab-grown tumor tissue predicts osteosarcoma chemotherapy responseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 May 2026